Agnathan VIP, PACAP and Their Receptors: Ancestral Origins of Today's Highly Diversified Forms

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ng, Stephanie Y L ^a   Chow, Billy K C ^a   Kasamatsu, Jun ^b   Kasahara, Masanori ^b   Lee, Leo T O ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; DUAL SPECIFICITY PHOSPHATASE 2; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; PHOSPHOLIPASE C; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; BIODIVERSITY; BRAIN; CALCIUM SIGNALING; ENZYME ACTIVITY; GENE DUPLICATION; GENETIC CONSERVATION; GENETIC DATABASE; HAGFISH; IN SITU HYBRIDIZATION; LAMPREY; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; PEPTIDE SYNTHESIS; PHYLOGENY; PLESIOMORPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

AGNATHA; EPTATRETUS BURGERI; HAGFISH; INVERTEBRATA; LETHENTERON JAPONICUM; PETROMYZON MARINUS; PETROMYZONTIDAE; VERTEBRATA;

EID: 84866016433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044691     Document Type: Article

References (72)

1. Said SI, Mutt V, (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169: 1217-1218.
2. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, et al. (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164: 567-574.
3. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S, (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8: 811-819.
4. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, et al. (1993) The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334: 3-8.
5. Hashimoto H, Ishihara T, Shigemoto R, Mori K, Nagata S, (1993) Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 11: 333-342.
6. Hosoya M, Onda H, Ogi K, Masuda Y, Miyamoto Y, et al. (1993) Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP). Biochem Biophys Res Commun 194: 133-143.
7. Morrow JA, Lutz EM, West KM, Fink G, Harmar AJ, (1993) Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP). FEBS Lett 329: 99-105.
8. Pisegna JR, Wank SA, (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci U S A 90: 6345-6349.
9. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, et al. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365: 170-175.
10. Svoboda M, Tastenoy M, Ciccarelli E, Stievenart M, Christophe J, (1993) Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I receptor. Biochem Biophys Res Commun 195: 881-888.
11. Holland PW, Garcia-Fernandez J, Williams NA, Sidow A (1994) Gene duplications and the origins of vertebrate development. Dev Suppl: 125-133.
12. Hoyle CH, (1998) Neuropeptide families: evolutionary perspectives. Regul Pept 73: 1-33.
13. Tse DL, Pang RT, Wong AO, Chan SM, Vaudry H, et al. (2002) Identification of a potential receptor for both peptide histidine isoleucine and peptide histidine valine. Endocrinology 143: 1327-1336.
14. Wu S, Roch GJ, Cervini LA, Rivier JE, Sherwood NM, (2008) Newly-identified receptors for peptide histidine-isoleucine and GHRH-like peptide in zebrafish help to elucidate the mammalian secretin superfamily. J Mol Endocrinol 41: 343-366.
15. Vandepoele K, De Vos W, Taylor JS, Meyer A, Van de Peer Y, (2004) Major events in the genome evolution of vertebrates: paranome age and size differ considerably between ray-finned fishes and land vertebrates. Proc Natl Acad Sci U S A 101: 1638-1643.
16. McRory J, Sherwood NM, (1997) Two protochordate genes encode pituitary adenylate cyclase-activating polypeptide and related family members. Endocrinology 138: 2380-2390.
17. Cardoso JC, Pinto VC, Vieira FA, Clark MS, Power DM, (2006) Evolution of secretin family GPCR members in the metazoa. BMC Evol Biol 6: 108.
18. Cardoso JC, Vieira FA, Gomes AS, Power DM, (2007) PACAP, VIP and their receptors in the metazoa: insights about the origin and evolution of the ligand-receptor pair. Peptides 28: 1902-1919.
19. Cardoso JC, Vieira FA, Gomes AS, Power DM, (2010) The serendipitous origin of chordate secretin peptide family members. BMC Evol Biol 10: 135.
20. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, et al. (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci U S A 91: 2679-2683.
21. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52: 269-324.
22. Ohno S (1970) Evolution by gene duplciation. New York: Springer-Verlag.
23. Kuraku S, Meyer A, Kuratani S, (2009) Timing of genome duplications relative to the origin of the vertebrates: did cyclostomes diverge before or after? Mol Biol Evol 26: 47-59.
24. Colbert EHM, Morales M, Minkoff EC (2001) Colbert's Evolution of the Vertebrates. New York, US: Wiley-Liss.
25. Duckert P, Brunak S, Blom N, (2004) Prediction of proprotein convertase cleavage sites. Protein Eng Des Sel 17: 107-112.
26. Holmgren S, Jensen J, (2001) Evolution of vertebrate neuropeptides. Brain Res Bull 55: 723-735.
27. Lee LT, Siu FK, Tam JK, Lau IT, Wong AO, et al. (2007) Discovery of growth hormone-releasing hormones and receptors in nonmammalian vertebrates. Proc Natl Acad Sci U S A 104: 2133-2138.
28. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, et al. (2000) Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275: 24003-24012.
29. Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P, et al. (1995) Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem Biophys Res Commun 206: 246-252.
30. Laburthe M, Couvineau A, Marie JC, (2002) VPAC receptors for VIP and PACAP. Receptors Channels 8: 137-153.
31. Nicole P, Du K, Couvineau A, Laburthe M, (1998) Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. J Pharmacol Exp Ther 284: 744-750.
32. Chow BK, Yuen TT, Chan KW, (1997) Molecular evolution of vertebrate VIP receptors and functional characterization of a VIP receptor from goldfish Carassius auratus. Gen Comp Endocrinol 105: 176-185.
33. Tams JW, Knudsen SM, Fahrenkrug J, (2001) Characterization of a G protein coupling "YL" motif of the human VPAC1 receptor, equivalent to the first two amino acids in the "DRY" motif of the rhodopsin family. J Mol Neurosci 17: 325-330.
34. Langer I, Robberecht P, (2005) Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation. Cell Signal 17: 17-24.
35. Okamoto T, Murayama Y, Hayashi Y, Inagaki M, Ogata E, et al. (1991) Identification of a Gs activator region of the beta 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell 67: 723-730.
36. Couvineau A, Lacapere JJ, Tan YV, Rouyer-Fessard C, Nicole P, et al. (2003) Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. J Biol Chem 278: 24759-24766.
37. Pisegna JR, Wank SA, (1996) Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 271: 17267-17274.
38. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, et al. (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170: 643-648.
39. Matsuda K, Yoshida T, Nagano Y, Kashimoto K, Yatohgo T, et al. (1998) Purification and primary structure of pituitary adenylate cyclase activating polypeptide (PACAP) from the brain of an elasmobranch, stingray, Dasyatis akajei. Peptides 19: 1489-1495.
40. Nelson JS (1994) Fishes of the World. New York, US: Wiley Press.
41. Montero M, Yon L, Kikuyama S, Dufour S, Vaudry H, (2000) Molecular evolution of the growth hormone-releasing hormone/pituitary adenylate cyclase-activating polypeptide gene family. Functional implication in the regulation of growth hormone secretion. J Mol Endocrinol 25: 157-168.
42. Campbell RM, Scanes CG, (1992) Evolution of the growth hormone-releasing factor (GRF) family of peptides. Growth Regul 2: 175-191.
43. Sherwood NM, Krueckl SL, McRory JE, (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21: 619-670.
44. Chakder S, Rattan S, (1993) The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. J Pharmacol Exp Ther 266: 392-399.
45. Robberecht P, Gourlet P, De Neef P, Woussen-Colle MC, Vandermeers-Piret MC, et al. (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur J Biochem 207: 239-246.
46. Vandermeers A, Vandenborre S, Hou X, de Neef P, Robberecht P, et al. (1992) Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes. Eur J Biochem 208: 815-819.
47. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, et al. (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61: 283-357.
48. Cauvin A, Buscail L, Gourlet P, De Neef P, Gossen D, et al. (1990) The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK. Peptides 11: 773-777.
49. Gottschall PE, Tatsuno I, Miyata A, Arimura A, (1990) Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 127: 272-277.
50. Gottschall PE, Tatsuno I, Arimura A, (1991) Hypothalamic binding sites for pituitary adenylate cyclase activating polypeptide: characterization and molecular identification. FASEB J 5: 194-199.
51. Suda K, Smith DM, Ghatei MA, Bloom SR, (1992) Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain. Neurosci Lett 137: 19-23.
52. Schafer H, Zheng J, Morys-Wortmann C, Folsch UR, Schmidt WE, (1999) Structural motifs of pituitary adenylate cyclase-activatin polypeptide (PACAP) defining PAC1-receptor selectivity. Regul Pept 79: 83-92.
53. Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, et al. (1996) C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors. Regul Pept 62: 125-130.
54. Nordstrom KJ, Lagerstrom MC, Waller LM, Fredriksson R, Schioth HB, (2009) The Secretin GPCRs descended from the family of Adhesion GPCRs. Mol Biol Evol 26: 71-84.
55. Nordstrom KJ, Fredriksson R, Schioth HB, (2008) The amphioxus (Branchiostoma floridae) genome contains a highly diversified set of G protein-coupled receptors. BMC Evol Biol 8: 9.
56. Kamesh N, Aradhyam GK, Manoj N, (2008) The repertoire of G protein-coupled receptors in the sea squirt Ciona intestinalis. BMC Evol Biol 8: 129.
57. Bentley PJ (1998) Comparative Vertebrate Endocrinology. Cambridge, UK: Cambridge University Press.
58. Ben-Shlomo I, Hsueh AJ, (2005) Three's company: two or more unrelated receptors pair with the same ligand. Mol Endocrinol 19: 1097-1109.
59. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
60. Abascal F, Zardoya R, Posada D, (2005) ProtTest: selection of best-fit models of protein evolution. Bioinformatics 21: 2104-2105.
61. O'Donnell M, Garippa RJ, O'Neill NC, Bolin DR, Cottrell JM, (1991) Structure-activity studies of vasoactive intestinal polypeptide. J Biol Chem 266: 6389-6392.
62. Gozes I, Fridkinb M, Hill JM, Brenneman DE, (1999) Pharmaceutical VIP: prospects and problems. Curr Med Chem 6: 1019-1034.
63. Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, et al. (1999) Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc Natl Acad Sci U S A 96: 4143-4148.
64. Onoue S, Nagano Y, Tatsuno I, Uchida D, Kashimoto K, (1999) Receptor-binding specificity depending on N-terminal structure of VIP/PACAP. Biomed Res 20: 219-231.
65. Igarashi H, Ito T, Hou W, Mantey SA, Pradhan TK, et al. (2002) Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig. J Pharmacol Exp Ther 301: 37-50.
66. Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, et al. (2002) Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors. J Pharmacol Exp Ther 303: 445-460.
67. Gourlet P, Vandermeers-Piret MC, Rathe J, De Neef P, Cnudde J, et al. (1998) Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. Eur J Pharmacol 348: 95-99.
68. Nachtergael I, Vertongen P, Langer I, Perret J, Robberecht P, et al. (2003) Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor. Biochem J 370: 1003-1009.
69. Robberecht P, Gourlet P, De Neef P, Woussen-Colle MC, Vandermeers-Piret MC, et al. (1992) Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21. Mol Pharmacol 42: 347-355.
70. Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, et al. (2007) Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci U S A 104: 7875-7880.
71. Bourgault S, Vaudry D, Couvineau A, Doan ND, Laburthe M, et al. (2008) Structure-activity relationship studies of pituitary adenylate cyclase-activating polypeptide: Ala-scan of the N-terminal domain. Proc 30th Eur Pept Symp: 352-353.
72. Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, et al. (2009) Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Curr Med Chem 16: 4462-4480.